Chronic erythropoietin treatment affects different molecular pathways of diabetic cardiomyopathy in mouse

European Journal of Clinical Investigation

Volumn 39, Issue 9, 2009, Pages 755-760

  Shushakova, N ^a   Park, J K ^a   Menne, J ^a   Fliser, D ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Atrial natriuretic peptide; Continuous erythropoietin receptor activator; Diabetic cardiomyopathy; Transforming growth factor beta

Indexed keywords

ATRIAL NATRIURETIC FACTOR; COLLAGEN TYPE 1; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; PLACEBO; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CONTROL GROUP; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; HEART PROTECTION; HEMATOCRIT; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; MALE; MICE; MYOCARDIUM; POLYETHYLENE GLYCOLS;

EID: 68349150378     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2009.02165.x     Document Type: Article

References (31)

1. Fliser D, Haller H. Erythropoietin and treatment of non-anemic conditions - cardiovascular protection. Semin Hematol 2007 44 : 212 7.
2. Lipsic E, Schoemaker RG, van der Meer P, Voors AA, van Veldhuisen DJ, van Gilst WH. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol 2006 48 : 2161 7.
3. Fliser D, Bahlmann FH, deGroot K, Haller H. Mechanisms of disease: erythropoietin - an old hormone with a new mission? Nat Clin Pract Cardiovasc Med 2006 3 : 563 72.
4. Menne J, Park JK, Shushakova N, Mengel M, Meier M, Fliser D. The continuous erythropoietin receptor activator affects different pathways of diabetic renal injury. J Am Soc Nephrol 2007 18 : 2046 53.
5. Tillmann HC, Kuhn B, Kranzlin B, Sadick M, Gross J, Gretz N et al. Efficacy and immunogenicity of novel erythropoietic agents and conventional rhEPO in rats with renal insufficiency. Kidney Int 2006 69 : 60 7.
6. Asbun J, Villarreal FJ. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 2006 47 : 693 700.
7. Fonarow GC, Srikanthan P. Diabetic cardiomyopathy. Endocrinol Metab Clin North Am 2006 35 : 575 99, ix.
8. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007 115 : 3213 23.
9. Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res 2006 98 : 596 605.
10. Severson DL. Diabetic cardiomyopathy: recent evidence from mouse models of type 1 and type 2 diabetes. Can J Physiol Pharmacol 2004 82 : 813 23.
11. Menne J, Park JK, Boehne M, Elger M, Lindschau C, Kirsch T et al. Diminished loss of proteoglycans and lack of albuminuria in protein kinase C-alpha-deficient diabetic mice. Diabetes 2004 53 : 2101 9.
12. Khaidar A, Marx M, Lubec B, Lubec G. L-arginine reduces heart collagen accumulation in the diabetic db/db mouse. Circulation 1994 90 : 479 83.
13. Skoza L, Giacomelli F, Wiener J. Lysosomal enzymes in the heart of the genetically diabetic mouse. Lab Invest 1980 43 : 443 8.
14. Mizushige K, Yao L, Noma T, Kiyomoto H, Yu Y, Hosomi N et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 2000 101 : 899 907.
15. Belmadani S, Bernal J, Wei CC, Pallero MA, Dell'italia L, Murphy-Ullrich JE et al. A thrombospondin-1 antagonist of transforming growth factor-beta activation blocks cardiomyopathy in rats with diabetes and elevated angiotensin II. Am J Pathol 2007 171 : 777 89.
16. Stritzke J, Mayer B, Lieb W, Luchner A, Doring A, Hense HW et al. Haematocrit levels and left ventricular geometry: results of the MONICA Augsburg Echocardiographic Substudy. J Hypertens 2007 25 : 1301 9.
17. Van den Bergh A, Flameng W, Herijgers P. Type II diabetic mice exhibit contractile dysfunction but maintain cardiac output by favourable loading conditions. Eur J Heart Fail 2006 8 : 777 83.
18. Bayerle-Eder M, Zangeneh M, Kreiner G, Raffesberg W, Nowotny P, Vierhapper H et al. ANP but not BNP reflects early left diastolic dysfunction in type 1 diabetics with myocardial dysinnervation. Horm Metab Res 2003 35 : 301 7.
19. Fredersdorf S, Thumann C, Ulucan C, Griese DP, Luchner A, Riegger GA et al. Myocardial hypertrophy and enhanced left ventricular contractility in Zucker diabetic fatty rats. Cardiovasc Pathol 2004 13 : 11 9.
20. Pidgeon GB, Richards AM, Nicholls MG, Espiner EA, Yandle TG, Frampton C. Differing metabolism and bioactivity of atrial and brain natriuretic peptides in essential hypertension. Hypertension 1996 27 : 906 13.
21. Tonolo G, Richards AM, Manunta P, Troffa C, Pazzola A, Madeddu P et al. Low-dose infusion of atrial natriuretic factor in mild essential hypertension. Circulation 1989 80 : 893 902.
22. Hayashi M, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Tsutsui T et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2001 37 : 1820 6.
23. Lai CP, Egashira K, Tashiro H, Narabayashi H, Koyanagi S, Imaizumi T et al. Beneficial effects of atrial natriuretic peptide on exercise-induced myocardial ischemia in patients with stable effort angina pectoris. Circulation 1993 87 : 144 51.
24. Herrmann HC, Rosenthal AD, Davis CA. Cardiovascular effects of intracoronary atrial natriuretic peptide administration in man. Am Heart J 1990 120 : 308 15.
25. Rosenthal AD, Moran M, Herrmann HC. Coronary hemodynamic effects of atrial natriuretic peptide in humans. J Am Coll Cardiol 1990 16 : 1107 13.
26. Kato T, Muraski J, Chen Y, Tsujita Y, Wall J, Glembotski CC et al. Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt. J Clin Invest 2005 115 : 2716 30.
27. Bahlmann FH, Song R, Boehm SM, Mengel M, von Wasielewski R, Lindschau C et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004 110 : 1006 12.
28. Kokot F, Wiecek A, Schmidt-Gayk H, Marcinkowski W, Nieszporek T, Rudka R et al. Influence of long-term erythropoietin therapy on endocrine abnormalities in haemodialyzed patients. Przegl Lek 1992 49 : 43 9.
29. Kokot F, Wiecek A, Grzeszczak W, Klin M. Influence of erythropoietin treatment on plasma renin activity, aldosterone, vasopressin and atrial natriuretic peptide in haemodialyzed patients. Miner Electrolyte Metab 1990 16 : 25 9.
30. Dyjas R, Bulanowski M, Ficek R, Witkowicz J, Chudek J, Wiecek A. Influence of recombinant human erythropoietin (rHuEPO) on plasma levels of selected hormones in females with rheumatoid arthritis. Pol Arch Med Wewn 2005 114 : 731 7.
31. Porat O, Neumann D, Zamir O, Nachshon S, Feigin E, Cohen J et al. Erythropoietin stimulates atrial natriuretic peptide secretion from adult rat cardiac atrium. J Pharmacol Exp Ther 1996 276 : 1162 8.